<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595787</url>
  </required_header>
  <id_info>
    <org_study_id>COHABILIT-IPC 2017-046</org_study_id>
    <nct_id>NCT03595787</nct_id>
  </id_info>
  <brief_title>COaching and Prehabilitation: Evaluation of an Early Multidisciplinary Approach in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome</brief_title>
  <acronym>COHABILIT</acronym>
  <official_title>COaching and Prehabilitation: Evaluation of an Early Multidisciplinary Approach in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome, Treated With Intensive Chemotherapy and Hematopoietic Stem Cells Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study aims to evaluate the graft-related mortality rate after the initiation of
      a multidisciplinary prehabilitation program.

      Patients will be included within 10 days after the initiation of their treatment. The
      prehabilitation will consist in a patient-tailored program based on: adapted physical
      activity, nutritional support and coaching.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2019</start_date>
  <completion_date type="Anticipated">January 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of transplant related mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of transplant related mortality defined as death due to causes unrelated to the underlying disease. Patients relapsing are censored as surviving at the time of relapse</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Prehabilitation program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coaching and Habilitation</intervention_name>
    <description>nutritional support, adapted physical activity and coaching</description>
    <arm_group_label>Prehabilitation program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acute myeloid leukemia or high-risk myelodysplastic syndrome

          -  Age between 18 and 70 years

          -  Eligible for an intensive chemotherapy

          -  Eligible for allograft

          -  Able to answer a questionnaire

        Exclusion Criteria:

          -  Diagnosis of acute promyelocytic Leukemia

          -  Palliative treatment

          -  Contraindication to moderate physical activity

          -  Performans status 4, unless it is related to the disease

          -  Patient who does not understand French

          -  Patient unable to use a smartphone

          -  Patient deprived of liberty or placed under the authority of a tutor,

          -  Patient considered socially or psychologically unable to comply with the treatment and
             the required medical follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cécile Bannier Braticevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique Genre, MD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihane Pakradouni, PharmD, PhD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominique Genre, MD</last_name>
      <phone>33 (0)4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jihane Pakradouni, PharmD, PhD</last_name>
      <phone>33 (0)4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cécile Braticevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prehabilitation</keyword>
  <keyword>coaching</keyword>
  <keyword>nutritional support</keyword>
  <keyword>physical activity</keyword>
  <keyword>allogeneic stem cells transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

